Table 2.
Clinical characteristics of patients according to assay results for C1q and C3d
| Clinical characteristics of patients | C1q | C3d | ||
|---|---|---|---|---|
| C1q+ (n = 32) | C1q− (n = 33) | C3d+ (n = 23) | C3d− (n = 42) | |
| Time to first DSA (years) | 2.6 (0.1–4.9) | 0.4 (0.1–2.1) | 2.3 (0.1–4.1) | 0.4 (0.1–3.1) |
| Sex, male | 21 (66%)** | 27 (82%)** | 15 (65%) | 33 (79%) |
| Cause of end-stage kidney disease | ||||
| CAKUT | 22 (69%)* | 12 (36%)* | 15 (65%) | 19 (45%) |
| Glomerulonephritis | 3 (9%) | 5 (15%) | 3 (13%) | 5 (12%) |
| Others | 7 (22%) | 16 (48%) | 5 (22%) | 18 (43%) |
| Mismatches | 2 (2–3) | 2 (2–3) | 2 (2–3) | 2 (2–3) |
| Age of transplant (years) | 7.2 (4.7–10.5) | 11.1 (5.6–13.9) | 7.3 (5.1–10.1) | 10.3 (5.2–13.8) |
| Donor type LD | 20 (63%) | 17 (52%) | 14 (61%) | 23 (55%) |
| Medication: | ||||
| Pred/Aza/Tac | 7 (24%) | 11 (35%) | 3 (18%)* | 15 (35%)* |
| Pred/Tac/MMF | 5 (17%) | 4 (13%) | 4 (24%)* | 5 (12%)* |
| Pred/MMF | 8 (28%) | 5 (26%) | 6 (35%)* | 7 (16%)* |
| Pred/Tac | 6 (21%) | 10 (32%) | 2 (12%)* | 14 (33%)* |
| Tac/MMF | 1 (3%) | 1 (3%) | 0 | 2 (5%) |
| Tac | 1 (3%) | 1 (5%) | ||
| MMF | 1 (3%) | 1 (5%) | ||
*, ** Significantly different at: *p < 0.05, **p < 0.005. Results are not significantly different unless otherwise stated
Results in table are presented at the median with the interquartile range (IQR) in parenthesis or as the frequency (number) with the percentage in parenthesis, as appropriate
CAKUT, Congenital anomalies of the kidney and urinary tract; LD, living donor;; Pred, prednisolone; Aza, azathioprine; Tac, tacrolimus; MMF, mycophenolate mofetil